Press Releases and Events
IntraPace Provides Update on German Reimbursement for abiliti® Weight Loss Management System
Clinics Offering abiliti System Receive NUB Approval for 2012
Mountain View, CA - March 5, 2012
IntraPace, Inc., the developer of the innovative abiliti® implantable weight loss management system, announced today that 17 specialist obesity clinics offering the procedure in Germany have received NUB (Neue Untersuchungs- und Behandlungsmethoden) approval.
The InEK (Institute for the Hospital Remuneration System), which controls hospital re-imbursement in Germany, created the NUB to provide funding for innovative medical products before the product is officially entered into the re-imbursement catalogue (G-DRG).
Each hospital needs to apply separately and the payment, if the application is approved, is only available in the hospital that applied and not to every hospital in Germany. Approved applications are subsequently monitored by the InEK and if the new technology is used appropriately, correctly coded and exhibits a cost profile of sufficient difference, it will be considered for permanent integration into to the G-DRG.
“The NUB pathway will enable IntraPace to accelerate market access in Germany for the abiliti system,” stated Chuck Brynelsen, President & CEO of IntraPace. “We have the most clinical experience with abiliti in Germany and welcome being able to offer patients our innovative weight loss product more rapidly.”
People interested in taking advantage of IntraPace’s NUB approval are encouraged to visit www.abiliti.com to find an NUB center near them.
About the abiliti System
Following implantation via a simple minimally invasive surgical procedure, the abiliti system detects when a person eats or drinks and sends low-level electrical impulses to the stomach. This stimulation is intended to help a person feel full before the stomach is actually full, causing them to eat less. As the anatomy of the stomach and intestines is not changed, clinical experience with the abiliti system has shown virtually none of the nausea, diarrhea and other side effects seen with gastric bypass surgery and gastric banding. Patients are not restricted in the types of food that they consume, but are encouraged to adopt a healthy diet and exercise program.
Further, this novel system automatically records when a patient eats, drinks and exercises. Using a simple wireless connection, patients and physicians can view the consumption and exercise data. Access to this important information provides an enormous benefit as it allows physicians and patients to understand patient behaviors and develop effective strategies for maintained weight loss. Additionally, the system connects patients to a valuable social support network (my.abiliti.com), which research has demonstrated can increase the effectiveness of weight loss programs.
IntraPace was founded in 2001 to address an unmet need in weight loss surgery by developing a gentler solution for weight loss that incorporates essential components of behavior therapy. The abiliti system enables patients to achieve and sustain significant weight loss without the complications, lifestyle restrictions and substantial anatomical changes associated with the established weight loss surgeries.
Based in Mountain View, California, IntraPace is backed by premier investors, including Boston Scientific, CB Health Ventures, DFJ ePlanet Ventures, InCube Ventures, Johnson & Johnson Development Corp., L Capital Partners, Oxford Bioscience Partners, Toucan Capital Corp, Angels’ Forum, Halo Fund and Vulcan Capital.
The abiliti system has CE Mark in the European Union. It is not approved for sale in the United States. For more information, visit www.abiliti.com.
Christopher Rowland, Chief Commercial Officer
Tel: +1 (650) 316 4075
Tel: +44 (0)20 7318 2959